Amicus Therapeutics, Inc. – LSE:0HF9.L
Amicus Therapeutics stock price today
Amicus Therapeutics stock price monthly change
Amicus Therapeutics stock price quarterly change
Amicus Therapeutics stock price yearly change
Amicus Therapeutics key metrics
Market Cap | 2.91B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.50 |
Revenue | 423.48M |
EBITDA | -74.58M |
Income | -147.07M |
Revenue Q/Q | 27.97% |
Revenue Y/Y | 25.74% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -17.61% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAmicus Therapeutics stock price history
Amicus Therapeutics stock forecast
Amicus Therapeutics financial statements
| Jun 2023 | 94.50M | -43.23M | -45.75% |
|---|---|---|---|
| Sep 2023 | 103.50M | -21.57M | -20.85% |
| Dec 2023 | 115.08M | -33.84M | -29.41% |
| Mar 2024 | 110.40M | -48.41M | -43.86% |
| Mar 2024 | 110.40M | -48.41M | -43.86% |
|---|---|---|---|
| Sep 2025 | 187.06M | 38.83M | 20.76% |
| Oct 2025 | 170.64M | 23.53M | 13.79% |
| Dec 2025 | 186.69M | 36.95M | 19.79% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 730093000 | 618.51M | 84.72% |
|---|---|---|---|
| Sep 2023 | 764084000 | 630.84M | 82.56% |
| Dec 2023 | 777880000 | 617.70M | 79.41% |
| Mar 2024 | 721789000 | 591.09M | 81.89% |
| Jun 2023 | -16.13M | 50.00M | 23.67M |
|---|---|---|---|
| Sep 2023 | -38.34M | 35.76M | 37.61M |
| Dec 2023 | 3.45M | -23.95M | 8.21M |
| Mar 2024 | -29.69M | 7.53M | -13.30M |
Amicus Therapeutics alternative data
| Aug 2023 | 484 |
|---|---|
| Sep 2023 | 484 |
| Oct 2023 | 484 |
| Nov 2023 | 484 |
| Dec 2023 | 484 |
| Jan 2024 | 484 |
| Feb 2024 | 484 |
| Mar 2024 | 517 |
| Apr 2024 | 517 |
| May 2024 | 517 |
| Jun 2024 | 517 |
| Jul 2024 | 517 |
Amicus Therapeutics other data
| Patent |
|---|
Grant Filling date: 18 Jan 2019 Issue date: 13 Sep 2022 |
Grant Filling date: 11 Feb 2022 Issue date: 30 Aug 2022 |
Grant Filling date: 18 Feb 2022 Issue date: 19 Jul 2022 |
Grant Filling date: 18 Feb 2022 Issue date: 19 Jul 2022 |
Grant Filling date: 11 Feb 2022 Issue date: 5 Jul 2022 |
Application Filling date: 15 Dec 2021 Issue date: 23 Jun 2022 |
Application Filling date: 29 Apr 2020 Issue date: 23 Jun 2022 |
Application Filling date: 14 Jan 2021 Issue date: 16 Jun 2022 |
Grant Filling date: 11 Feb 2022 Issue date: 14 Jun 2022 |
Grant Filling date: 11 Feb 2022 Issue date: 14 Jun 2022 |
-
What's the price of Amicus Therapeutics stock today?
One share of Amicus Therapeutics stock can currently be purchased for approximately $11.81.
-
When is Amicus Therapeutics's next earnings date?
Unfortunately, Amicus Therapeutics's (0HF9.L) next earnings date is currently unknown.
-
Does Amicus Therapeutics pay dividends?
No, Amicus Therapeutics does not pay dividends.
-
How much money does Amicus Therapeutics make?
Amicus Therapeutics has a market capitalization of 2.91B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.3% to 399.36M US dollars.
-
What is Amicus Therapeutics's stock symbol?
Amicus Therapeutics, Inc. is traded on the LSE under the ticker symbol "0HF9.L".
-
What is Amicus Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Amicus Therapeutics?
Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Amicus Therapeutics have?
As Jul 2024, Amicus Therapeutics employs 517 workers.
-
When Amicus Therapeutics went public?
Amicus Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Amicus Therapeutics's official website?
The official website for Amicus Therapeutics is amicusrx.com.
-
Where are Amicus Therapeutics's headquarters?
Amicus Therapeutics is headquartered at 3675 Market Street, Philadelphia, PA.
-
How can i contact Amicus Therapeutics?
Amicus Therapeutics's mailing address is 3675 Market Street, Philadelphia, PA and company can be reached via phone at 215 921 7600.
Amicus Therapeutics company profile:
Amicus Therapeutics, Inc.
amicusrx.comLSE
500
Medical - Pharmaceuticals
Healthcare
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Philadelphia, PA 19104
:
ISIN: US03152W1099
:
